LNO-M02

LNO-M02 is a developmental asset being advanced by Linno Pharmaceuticals (Lingnuo Pharmaceuticals). According to company pipeline data, the identifier LNO-M02 is associated with two distinct programs: an mRNA-based therapeutic for the treatment of infectious diseases currently in preclinical development, and a monoclonal antibody (mAb) targeting solid tumors which is in the IND-enabling phase. The mRNA program is specifically linked to development efforts in the United States, while the monoclonal antibody program is associated with development in Australia. As a preclinical asset, specific molecular targets and the exact nature of the infectious pathogens or tumor types addressed have not been publicly disclosed.